AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8435259 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium 70 micrograms kg‐1
Number of subjects: 40
Study 8435259 — intervention group
Group type: COMPARATOR
Intervention: Tubocurarine 0.5 mg kg‐1
Number of subjects: 40
Study 3657041 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50-100 mg/day)
Number of subjects: 50
Study 3657041 — intervention group
Group type: COMPARATOR
Intervention: Untreated essential hypertension
Number of subjects: 50
Study 3657041 — intervention group
Group type: COMPARATOR
Intervention: Mechanical stress on RBCs
Number of subjects: 50
Study 31362007 — intervention group
Group type: EXPERIMENTAL
Intervention: Clip closure of mucosal defects using 11-mm through-the-scope clips (n=119)
Number of subjects: 235
Study 31362007 — intervention group
Group type: COMPARATOR
Intervention: No clip closure (control group, n=116)
Number of subjects: 235
Study 31362007 — intervention group
Group type: EXPERIMENTAL
Intervention: Clip closure of mucosal defects using 11-mm through-the-scope clips (n=119) after complete closure
Number of subjects: 235
Study 28734853 — intervention group
Group type: EXPERIMENTAL
Intervention: D25 (dexmedetomidine 25 μg kg−1)
Number of subjects: 8
Study 28734853 — intervention group
Group type: EXPERIMENTAL
Intervention: D25M300 (dexmedetomidine 25 μg kg−1 + MK-467 300 μg kg−1)
Number of subjects: 8
Study 28734853 — intervention group
Group type: EXPERIMENTAL
Intervention: D25M600 (dexmedetomidine 25 μg kg−1 + MK-467 600 μg kg−1)
Number of subjects: 8
Study 28734853 — intervention group
Group type: EXPERIMENTAL
Intervention: D25M1200 (dexmedetomidine 25 μg kg−1 + MK-467 1200 μg kg−1)
Number of subjects: 8
Study 28734853 — intervention group
Group type: EXPERIMENTAL
Intervention: M600 (MK-467 600 μg kg−1)
Number of subjects: 8
Study 28734853 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments with dexmedetomidine
Number of subjects: 8
Study 25912372 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational interventions to increase HPV vaccination coverage
Number of subjects: 0
Study 23909490 — intervention group
Group type: EXPERIMENTAL
Intervention: ERCC1 rs11615 A/A genotype
Number of subjects: 384
Study 23909490 — intervention group
Group type: EXPERIMENTAL
Intervention: XPF rs6498486 C/C genotype
Number of subjects: 384
Study 23909490 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ERCC1 rs11615 A allele and XPF rs6498486 C allele
Number of subjects: 384
Study 21339423 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass with duodenum exclusion (n = 30)
Number of subjects: 60
Study 21339423 — intervention group
Group type: COMPARATOR
Intervention: Sleeve gastrectomy without duodenum exclusion (n = 30)
Number of subjects: 60
Study 19506498 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine (2 microg/kg)
Number of subjects: 100
Study 19506498 — intervention group
Group type: COMPARATOR
Intervention: Oral midazolam (0.5 mg/kg)
Number of subjects: 100
Study 16484572 — intervention group
Group type: EXPERIMENTAL
Intervention: Aged garlic extract (AGE) administered for 6 months
Number of subjects: 50
Study 16484572 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered for 6 months
Number of subjects: 50
Study 15172399 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 3541
Study 15172399 — intervention group
Group type: COMPARATOR
Intervention: Balloon Angioplasty
Number of subjects: 3541
Study 10386195 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (400‐800 mg/d p.o.)
Number of subjects: 20
Study 10386195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8926223 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention (differential reinforcement of appropriate behavior and guided compliance)
Number of subjects: 3
Study 8926223 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (Ritalin)
Number of subjects: 3
Study 8926223 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined effects of behavioral intervention and methylphenidate
Number of subjects: 3
Study 1520082 — intervention group
Group type: EXPERIMENTAL
Intervention: Threonine at a total daily dose of 7.5 g
Number of subjects: 26
Study 1520082 — intervention group
Group type: EXPERIMENTAL
Intervention: Threonine
Number of subjects: 26
Study 6873148 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 75 mg at 20 h
Number of subjects: 0
Study 6873148 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 75 mg at 8 h
Number of subjects: 0
Study 6873148 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 75 mg at 12 h
Number of subjects: 0
Study 29756695 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulating catheter (Stim group, N=36)
Number of subjects: 72
Study 29756695 — intervention group
Group type: COMPARATOR
Intervention: Nonstimulating catheter (Nonstim group, N=36)
Number of subjects: 72
Study 27806013 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training Group (STG)
Number of subjects: 86
Study 27806013 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 86
Study 25833885 — intervention group
Group type: EXPERIMENTAL
Intervention: Modeling group (n = 160)
Number of subjects: 407
Study 25833885 — intervention group
Group type: COMPARATOR
Intervention: Validation group (n = 247)
Number of subjects: 407
Study 23093133 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 0
Study 23093133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20868641 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 1460
Study 20868641 — intervention group
Group type: COMPARATOR
Intervention: Second-generation antipsychotics (olanzapine, quetiapine, risperidone, ziprasidone)
Number of subjects: 1460
Study 20868641 — intervention group
Group type: COMPARATOR
Intervention: Perphenazine (first-generation antipsychotic)
Number of subjects: 1460
Study 17940309 — intervention group
Group type: EXPERIMENTAL
Intervention: Preganglionic TFESI (at the supraadjacent intervertebral disk level)
Number of subjects: 239
Study 17940309 — intervention group
Group type: COMPARATOR
Intervention: Ganglionic TFESI (at the location of the exiting nerve root)
Number of subjects: 239
Study 15531056 — intervention group
Group type: EXPERIMENTAL
Intervention: Class 1 obese subjects
Number of subjects: 50
Study 15531056 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index correlation
Number of subjects: 50
Study 15531056 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic pedobarographic parameters
Number of subjects: 50
Study 12351450 — intervention group
Group type: EXPERIMENTAL
Intervention: C-peptide (6 pmol x kg(‐1) x min(‐1)) during 60 min
Number of subjects: 8
Study 12351450 — intervention group
Group type: COMPARATOR
Intervention: Saline during 60 min
Number of subjects: 8
Study 10543928 — intervention group
Group type: EXPERIMENTAL
Intervention: ramipril 5 mg/day
Number of subjects: 98
Study 10543928 — intervention group
Group type: EXPERIMENTAL
Intervention: ramipril 1.25 mg/day
Number of subjects: 98
Study 10543928 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 98
Study 7558732 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 142
Study 7558732 — intervention group
Group type: COMPARATOR
Intervention: Ioxaglate
Number of subjects: 142
Study 7558732 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol and Ioxaglate
Number of subjects: 142
Study 2207219 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine hydrochloride (CMI)
Number of subjects: 0
Study 2207219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6447269 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH 1000 (40 microgram ipratropium bromide)
Number of subjects: 27
Study 6447269 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (400 microgram)
Number of subjects: 27
Study 6447269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 6392223 — intervention group
Group type: EXPERIMENTAL
Intervention: AT1727 as a radiosensitizer
Number of subjects: 89
Study 6392223 — intervention group
Group type: EXPERIMENTAL
Intervention: AT1727 in soft tissue sarcomas
Number of subjects: 89
Study 6392223 — intervention group
Group type: EXPERIMENTAL
Intervention: AT1727 in lung cancer
Number of subjects: 89
Study 6392223 — intervention group
Group type: EXPERIMENTAL
Intervention: AT1727 in esophageal cancer
Number of subjects: 89
Study 6392223 — intervention group
Group type: EXPERIMENTAL
Intervention: AT1727 in nasopharyngeal cancer
Number of subjects: 89
Study 6392223 — intervention group
Group type: EXPERIMENTAL
Intervention: AT1727 treatment side effects
Number of subjects: 89
Study 6392223 — intervention group
Group type: COMPARATOR
Intervention: Comparison of lung fibrosis rate
Number of subjects: 89
Study 29975672 — intervention group
Group type: EXPERIMENTAL
Intervention: Conflict resolution training session (3 hours)
Number of subjects: 60
Study 26724833 — intervention group
Group type: EXPERIMENTAL
Intervention: Two 20-min bouts of moderate-intensity physical activity
Number of subjects: 56
Study 26724833 — intervention group
Group type: COMPARATOR
Intervention: One 20-min bout of moderate-intensity physical activity
Number of subjects: 56
Study 26724833 — intervention group
Group type: COMPARATOR
Intervention: Control group (sitting all morning)
Number of subjects: 56
Study 24927259 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilirubin/albumin (B/A) ratio and total serum bilirubin (TSB) thresholds
Number of subjects: 615
Study 24927259 — intervention group
Group type: COMPARATOR
Intervention: Total serum bilirubin (TSB) thresholds only
Number of subjects: 615
Study 24927259 — intervention group
Group type: EXPERIMENTAL
Intervention: B/A ratio
Number of subjects: 615
Study 24927259 — intervention group
Group type: COMPARATOR
Intervention: TSB
Number of subjects: 615
Study 23113947 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyronaridine-artesunate granules (60/20 mg) once daily for three days
Number of subjects: 535
Study 23113947 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine crushed tablets (20/120 mg) twice daily for three days
Number of subjects: 535
Study 23113947 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyronaridine-artesunate
Number of subjects: 535
Study 23113947 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine
Number of subjects: 535
Study 23113947 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 535
Study 19648772 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (0.3 mg/kg/8 h p.o. for at least 2 days)
Number of subjects: 22
Study 19648772 — intervention group
Group type: COMPARATOR
Intervention: Sterile water (control)
Number of subjects: 22
Study 18348296 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy after primary surgery
Number of subjects: 506
Study 18348296 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age (>/=60 years)
Number of subjects: 506
Study 18348296 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage II cancer
Number of subjects: 506
Study 18348296 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 2 cancer
Number of subjects: 506
Study 18348296 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 3 cancer
Number of subjects: 506
Study 18348296 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive cytology
Number of subjects: 506
Study 18348296 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic index based on risk factors
Number of subjects: 506
Study 15785069 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 0
Study 15785069 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 0
Study 15785069 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment
Number of subjects: 0
Study 12509376 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacists consulting to family physicians for medication optimization
Number of subjects: 720
Study 12509376 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pharmacist consultation)
Number of subjects: 720
Study 12509376 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean systolic blood pressure
Number of subjects: 720
Study 12509376 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication use, health care utilization, and general health
Number of subjects: 720
Study 10594068 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned Stimuli (CS+)
Number of subjects: 0
Study 10594068 — intervention group
Group type: COMPARATOR
Intervention: Nonconditioned Stimuli (CS-)
Number of subjects: 0
Study 7532157 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial hepatic route (i.a.h.) administration of Cisplatin (CDDP)
Number of subjects: 22
Study 7532157 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (i.v.) administration of Cisplatin (CDDP)
Number of subjects: 22
Study 1821700 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose of milnacipran (300 mg daily for 2 weeks, then 150 mg daily for 2 weeks)
Number of subjects: 120
Study 1821700 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard regimen of milnacipran (200 mg daily for 4 weeks)
Number of subjects: 120
Study 1821700 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine (200 mg daily for 4 weeks)
Number of subjects: 120
Study 6896140 — intervention group
Group type: EXPERIMENTAL
Intervention: Massaging the nasolacrimal sac to increase hydrostatic pressure and rupture the membranous obstruction
Number of subjects: 132
Study 6896140 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple obstructions in the nasolacrimal duct
Number of subjects: 132
Study 6896140 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone intubation of the nasolacrimal system
Number of subjects: 132
Study 6896140 — intervention group
Group type: COMPARATOR
Intervention: Simple massage
Number of subjects: 132
Study 6896140 — intervention group
Group type: COMPARATOR
Intervention: No massage
Number of subjects: 132
Study 31871108 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (2,000 IU/day)
Number of subjects: 226
Study 31871108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study 31088405 — intervention group
Group type: EXPERIMENTAL
Intervention: MATESmobile + face-to-face training
Number of subjects: 590
Study 31088405 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face training
Number of subjects: 590
Study 29017527 — intervention group
Group type: EXPERIMENTAL
Intervention: ParentCorps
Number of subjects: 0
Study 29017527 — intervention group
Group type: COMPARATOR
Intervention: Standard pre-kindergarten programming
Number of subjects: 0
Study 27140216 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam sequential with dexmedetomidine (loading dose of midazolam at 0.3-3 mg/kg·h for 24 h before extubation, followed by dexmedetomidine infusion at 0.2-1 μg/kg·h until extubation)
Number of subjects: 80
Study 27140216 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (0.3-3 mg/kg·h until extubation)
Number of subjects: 80
Study 27140216 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam sequential with dexmedetomidine
Number of subjects: 80
Study 27140216 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 80
Study 24815795 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (titrated to 80 mg, three times daily, as tolerated)
Number of subjects: 0
Study 22348451 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose melatonin (0.4mg)
Number of subjects: 27
Study 22348451 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose melatonin (4.0mg)
Number of subjects: 27
Study 18822087 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine infusion
Number of subjects: 4
Study 18822087 — intervention group
Group type: COMPARATOR
Intervention: Levodopa infusion
Number of subjects: 4
Study 17473042 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Prompt L-Pop
Number of subjects: 60
Study 17473042 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 60
Study 17473042 — intervention group
Group type: EXPERIMENTAL
Intervention: FL Bond
Number of subjects: 60
Study 17473042 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond
Number of subjects: 60
Study 17473042 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeno III
Number of subjects: 60
Study 15190731 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal hypnosis
Number of subjects: 520
Study 15190731 — intervention group
Group type: COMPARATOR
Intervention: Attention-only group
Number of subjects: 520
Study 11357167 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1 receptor antagonist (IL-1ra) 150 mg/d
Number of subjects: 472
Study 11357167 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1ra (various dosages)
Number of subjects: 472
Study 11357167 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1ra 1.0 mg/kg/d
Number of subjects: 472
Study 11357167 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1ra 2.0 mg/kg/d
Number of subjects: 472
Study 11357167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 472
Study 9580575 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg LAAM
Number of subjects: 16
Study 9580575 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg LAAM
Number of subjects: 16
Study 9580575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8111576 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 N HCl
Number of subjects: 22
Study 8111576 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 22
Study 8111576 — intervention group
Group type: EXPERIMENTAL
Intervention: HCl infusion (patients)
Number of subjects: 22
Study 8111576 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% lignocaine
Number of subjects: 22
Study 3168576 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 26
Study 3168576 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 26
Study 3168576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 31160807 — intervention group
Group type: EXPERIMENTAL
Intervention: Second allogeneic hematopoietic cell transplant (allo‐HCT)
Number of subjects: 0
Study 31023084 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (150 min per week)
Number of subjects: 75
Study 31023084 — intervention group
Group type: COMPARATOR
Intervention: Albuminuria patients
Number of subjects: 75
Study 31023084 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 75
Study 28089672 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% isopropyl alcohol
Number of subjects: 1102
Study 28089672 — intervention group
Group type: COMPARATOR
Intervention: 2% chlorhexidine gluconate in 70% isopropyl alcohol
Number of subjects: 1102
Study 25594912 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training using exercises at the same intensity
Number of subjects: 90
Study 25594912 — intervention group
Group type: COMPARATOR
Intervention: Strength training using exercises of varying intensity
Number of subjects: 90
Study 23686001 — intervention group
Group type: EXPERIMENTAL
Intervention: Panretinal photocoagulation (PRP) associated with intravitreal bevacizumab (IVB) injections
Number of subjects: 42
Study 23686001 — intervention group
Group type: COMPARATOR
Intervention: Panretinal photocoagulation (PRP) alone
Number of subjects: 42
Study 20946162 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rehabilitation (sildenafil citrate twice weekly starting at 2 months postoperatively)
Number of subjects: 18
Study 20946162 — intervention group
Group type: COMPARATOR
Intervention: Late rehabilitation (sildenafil citrate twice weekly starting at 6 months postoperatively)
Number of subjects: 18
Study 19941182 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived deviations during simple machine work
Number of subjects: 12
Study 19941182 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived deviations during complex machine work
Number of subjects: 12
Study 16381002 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen for 2 years
Number of subjects: 377
Study 16381002 — intervention group
Group type: EXPERIMENTAL
Intervention: High HIF‐1α expression in lymph node-positive patients and NHG 1/2 tumours
Number of subjects: 377
Study 16381002 — intervention group
Group type: EXPERIMENTAL
Intervention: High HIF‐1α expression in NHG 1/2 tumours
Number of subjects: 377
Study 16381002 — intervention group
Group type: COMPARATOR
Intervention: Untreated control patients
Number of subjects: 377
Study 15263787 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic catheter (group B, n = 50)
Number of subjects: 100
Study 15263787 — intervention group
Group type: COMPARATOR
Intervention: Standard catheter (group A, n = 50)
Number of subjects: 100
Study 11419823 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard U.S. 13C‐urea breath test (125 mg of 13C‐urea, pudding test meal, breath sample taken 30 min after ingestion)
Number of subjects: 259
Study 11419823 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified UBT‐Lite (75 mg of 13C‐urea, 2.5-g citric acid test meal, breath sample taken 15 min after ingestion)
Number of subjects: 259
Study 11419823 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior meals versus fasting with UBT‐Lite
Number of subjects: 259
Study 9060555 — intervention group
Group type: EXPERIMENTAL
Intervention: Autotransplant (CBV regimen: cyclophosphamide, carmustine, and etoposide)
Number of subjects: 541
Study 9060555 — intervention group
Group type: COMPARATOR
Intervention: Sequential chemotherapy
Number of subjects: 541
Study 9060555 — intervention group
Group type: EXPERIMENTAL
Intervention: Autotransplant (CBV regimen)
Number of subjects: 541
Study 8376441 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma locking nail
Number of subjects: 200
Study 8376441 — intervention group
Group type: COMPARATOR
Intervention: Dynamic Hip Screw
Number of subjects: 200
Study 3545173 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalkon Shield
Number of subjects: 843
Study 3545173 — intervention group
Group type: EXPERIMENTAL
Intervention: 7Cu200
Number of subjects: 843
Study 3545173 — intervention group
Group type: EXPERIMENTAL
Intervention: Latex Leaf
Number of subjects: 843
Study 3545173 — intervention group
Group type: EXPERIMENTAL
Intervention: ML Cu250
Number of subjects: 843
Study 31553254 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose EGF
Number of subjects: 3
Study 31553254 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose EGF
Number of subjects: 3